Automated Insulin Delivery in Complex Cases: What One Woman's Experience Teaches Us

People living with type 1 diabetes sometimes develop kidney disease as a long-term complication. When kidney function declines severely, patients may need dialysis—a treatment that filters waste from the blood when the kidneys can no longer do this job. One form of dialysis, called peritoneal dialysis, uses the lining of the belly to filter blood at home.

Managing type 1 diabetes becomes even more complex when kidney disease is involved. Blood sugar patterns can change, insulin needs shift, and coordinating multiple treatments becomes challenging. For years, doctors weren't sure whether the latest insulin delivery technology would work safely in this situation.

Researchers recently reported on one woman with type 1 diabetes who was on peritoneal dialysis and used an automated insulin delivery system—specifically the Medtronic MiniMed 780G combined with a continuous glucose monitor. The system automatically adjusts insulin doses based on blood sugar readings throughout the day and night.

The woman faced additional obstacles beyond diabetes and kidney disease: she had visual impairment and a complete language barrier with her medical team. Despite these challenges, the transition from manual insulin injections to the automated system moved forward.

The case report compared blood sugar control in two time periods: the 14 days before starting the automated system (while on insulin injections) and 9 months after switching to automated delivery. The data showed improvement in her glycemic control after making the switch.

This positive outcome in a single patient suggests that automated insulin delivery could be a safe and helpful option for people managing both type 1 diabetes and end-stage kidney disease on dialysis. However, the researchers emphasized that this is one person's experience, not proof that the system works for everyone in this situation.

The authors concluded that automated insulin delivery 'might be a safe and promising therapeutic option' for people with type 1 diabetes and kidney disease requiring dialysis. At the same time, they were clear that further research is needed to confirm both safety and effectiveness in this special population.

Researchers also noted the importance of studying how patients feel about using this technology—their quality of life, confidence, and overall satisfaction—not just their blood sugar numbers. Before automated insulin delivery becomes standard practice for people on dialysis, more cases and larger studies will help doctors understand when and how to use it most effectively.

Source: Therapeutic advances in endocrinology and metabolism. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.